Shattuck Labs, Inc.
STTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeShattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The $719.2M market capitalization puts STTK squarely in small-cap range for its industry. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Market Cap
$719.2M
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-14.60
EPS (TTM)
$-0.60
EPS (Fwd)
$-0.52
ROE
-61.0%
ROA
-36.7%
Cash
$90.4M
Total Debt
$2.9M
Free CF
-$22.4M
52W Change
830.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $90.4M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$22.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -61.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $652K (2022) to $1.0M (2025), reflecting a 53% increase over the period.
With cash comfortably exceeding debt, STTK has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Shattuck Labs, Inc. and its sector.